The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making

Jenna Morgan*, Vinton Cheng, Peter Barry, Ellen Copson, Ramsey Cutress, Rajiv Dave, Beatrix Elsberger, Patricia Fairbrother, Sue Hartup, Brian Hogan, Kieran Horgan, Cliona Kirwan, Stuart McIntosh, Rachel O'Connell, Neill Patani, Shelley Potter, Tim Rattay, Lisa Sheehan, Lynda Wyld, Baek Kim

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

8 Citations (Scopus)
47 Downloads (Pure)

Abstract

Introduction
Evidence based guidelines for the optimal management of breast cancer locoregional recurrence (LRR) are limited, with potential for variation in clinical practice. This national practice questionnaire (NPQ) was designed to establish the current practice of UK breast multidisciplinary teams (MDTs) regarding LRR management.

Methods
UK breast units were invited to take part in the MARECA study MDT NPQ. Scenario-based questions were used to elicit preference in pre-operative staging investigations, surgical management, and adjuvant therapy.

Results
822 MDT members across 42 breast units (out of 144; 29%) participated in the NPQ (February-August 2021). Most units (95%) routinely performed staging CT scan, but bone scan was selectively performed (31%). For patients previously treated with breast conserving surgery (BCS) and radiotherapy, few
units (7%) always/usually offered repeat BCS. However, in the absence of radiotherapy, most units (90%) always/usually offered repeat BCS. For patients presenting with isolated local recurrence following previous BCS and SLNB (sentinel lymph node biopsy), most units (95%) advocated repeat SLNB. Where SLNs could not be identified, 86% proceeded to a four-node axillary sampling procedure. For ER+HER2- node negative local recurrence, 10% of units always/usually offered chemotherapy. For ER+HER2- node positive local recurrence, this recommendation increased to 64%. For triple negative breast cancer local recurrence, 90% of units always/usually offered chemotherapy.

Conclusion
This survey has highlighted where consistencies and variations exist in the multidisciplinary management of breast cancer LRR. However, further research is required to determine how these management patterns influence patient outcomes, which will further refine optimal treatment pathways.
Original languageEnglish
Pages (from-to)1510-1519
Number of pages28
JournalEuropean Journal of Surgical Oncology
Volume48
Issue number7
Early online date4 Apr 2022
DOIs
Publication statusE-pub ahead of print - 4 Apr 2022

Bibliographical note

Funding Information:
The MARECA study was funded by grants from the Association of Breast Surgery and Leeds Hospitals Charity . The funders had no role in the design of the study nor collection of data, and had no input into the analysis or interpretation of the data.

Publisher Copyright:
© 2022 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • breast cancer
  • recurrence
  • metastases
  • locoregional

Fingerprint

Dive into the research topics of 'The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making'. Together they form a unique fingerprint.

Cite this